Karyopharm bags a $193M Asian deal for selinexor and followup drug, shares jump
Karyopharm Therapeutics $KPTI has inked a regional Asian deal for its late-stage cancer therapy selinexor and a follow-up compound it has in the pipeline. Ono is paying $22.3 million upfront to grab development and commercial rights to the two therapies for a slate of countries that includes Japan, South Korea and Hong Kong. Ono is also on the hook for up to $170.7 million in milestones.
Karyopharm shares jumped 12% on the news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.